L3VLUP
ProSign in

NTLA · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NTLALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NTLA
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterNTLALLY
Q3 20203 holders, $241m33 holders, $14.1bn
Q4 20209 holders, $709m29 holders, $17.3bn
Q1 202110 holders, $1.1bn24 holders, $23.0bn
Q2 202111 holders, $2.6bn24 holders, $27.8bn
Q3 202113 holders, $2.2bn31 holders, $29.9bn
Q4 202111 holders, $2.1bn31 holders, $34.7bn
Q1 20228 holders, $1.0bn24 holders, $35.3bn
Q2 20227 holders, $721m33 holders, $42.7bn
Q3 20227 holders, $892m31 holders, $43.4bn
Q4 20227 holders, $476m31 holders, $46.6bn
Q1 20237 holders, $575m33 holders, $44.3bn
Q2 20236 holders, $538m37 holders, $59.6bn
Q3 20234 holders, $366m44 holders, $67.6bn
Q4 20236 holders, $446m45 holders, $73.6bn
Q1 20247 holders, $412m41 holders, $95.3bn
Q2 20246 holders, $332m43 holders, $110bn
Q3 20245 holders, $310m45 holders, $107bn
Q4 20247 holders, $220m46 holders, $93.9bn
Q1 20253 holders, $110m42 holders, $98.4bn
Q2 20255 holders, $170m43 holders, $93.2bn
Q3 20257 holders, $333m39 holders, $86.7bn
Q4 20255 holders, $166m41 holders, $123bn
Q1 20265 holders, $342m39 holders, $106bn
Q2 20266 holders, $537m44 holders, $132bn
NTLA

Intellia Therapeutics Inc

Holders
5
Reported value
$342m
Buyers
18
Sellers
14

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NTLA (1)

PDT Partners LLC

Only LLY (35)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 10 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →